Value through Innovation27 July 2016

Clinical Study Results

  • JARDIANCE ® - Diabetes Mellitus, Type 1
    Clinical Study Number 1245.78
    Study Indication Diabetes Mellitus, Type 1
    Product JARDIANCE ®
    Generic Name Empagliflozin
    Lab Code
    Clinical Phase IIa
    Study Title

    A 28-day randomised, placebo-controlled, double-blind parallel group phase IIa trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of 2.5 mg, 10 mg, and 25 mg empagliflozin as adjunctive to insulin in patients with type 1 diabetes mellitus (EASE-1)

    Study Document Trial synopsis 1245.78 english
  • JARDIANCE ® - Diabetes Mellitus, Type 1
    Clinical Study Number 1245.46
    Study Indication Diabetes Mellitus, Type 1
    Product JARDIANCE ®
    Generic Name Empagliflozin
    Lab Code
    Clinical Phase II
    Study Title

    An open-label 8-week adjunctive-to-insulin and renal mechanistic pilot trial of BI 10773 in type 1 diabetes mellitus (the ATIRMA trial)

    Study Document Trial synopsis 1245.46_DS_CO english
  • JARDIANCE ® - Diabetes Mellitus, Type 1
    Clinical Study Number 1245.113
    Study Indication Diabetes Mellitus, Type 1
    Product JARDIANCE ®
    Generic Name Empagliflozin
    Lab Code
    Clinical Phase II
    Study Title

    A phase II, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily, oral doses of empagliflozin as adjunctive to insulin therapy for 28 days in Japanese patients with type 1 diabetes mellitus

    Study Document Trial synopsis 1245.113 english
  • JARDIANCE ® - Diabetes Mellitus, Type 1
    Clinical Study Number 1245.69
    Study Indication Diabetes Mellitus, Type 1
    Product JARDIANCE ®
    Generic Name Empaglifozin
    Lab Code
    Clinical Phase III
    Study Title

    A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 Diabetes Mellitus (EASE-2)

    Study Document Trial synopsis 1245.69 english
  • JARDIANCE ® - Diabetes Mellitus, Type 1
    Clinical Study Number 1245.72
    Study Indication Diabetes Mellitus, Type 1
    Product JARDIANCE ®
    Generic Name Empagliflozin
    Lab Code
    Clinical Phase III
    Study Title

    A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 26 weeks in patients with Type 1 Diabetes Mellitus (EASE-3)

    Study Document Trial synopsis 1245.72 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.